Get the Stockscreener App
1.41
11.02%
0.14
After Hours:
1.42
0.01
+0.71%
Soligenix Inc stock is traded at $1.41, with a volume of 232.48K.
It is up +11.02% in the last 24 hours and down -14.55% over the past month.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
See More
Previous Close:
$1.27
Open:
$1.26
24h Volume:
232.48K
Relative Volume:
0.20
Market Cap:
$14.22M
Revenue:
$960.60K
Net Income/Loss:
$-7.10M
P/E Ratio:
-0.1865
EPS:
-7.56
Net Cash Flow:
$-8.00M
1W Performance:
+2.92%
1M Performance:
-14.55%
6M Performance:
-25.00%
1Y Performance:
-58.04%
1-Day Range:
$1.26
$1.43
1-Week Range:
$1.26
$1.47
52-Week Range:
$1.09
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Name
Soligenix Inc
Sector
Industry
Phone
609-538-8200
Address
29 EMMONS DRIVE, PRINCETON
Compare SNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.41 | 12.81M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-20 | Downgrade | Dawson James | Buy → Neutral |
| Jan-31-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-14-17 | Reiterated | Maxim Group | Buy |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
Soligenix Inc Stock (SNGX) Latest News
What insider purchases suggest about Soligenix Inc. (DOA0) stockPortfolio Value Summary & Accurate Intraday Trade Tips - newser.com
Will Soligenix Inc. (DOA) stock see valuation expansionJuly 2025 Momentum & Accurate Technical Buy Alerts - newser.com
Why Soligenix Inc. stock attracts high net worth investorsTrade Entry Summary & Advanced Swing Trade Entry Plans - newser.com
How Soligenix Inc. stock responds to policy changesMarket Trend Review & Accurate Trade Setup Notifications - newser.com
What insider trading reveals about Soligenix Inc. stockTrade Entry Report & Risk Managed Investment Strategies - newser.com
Will Soligenix Inc. (DOA0) stock gain from lower interest ratesJuly 2025 Macro Moves & Reliable Price Breakout Signals - newser.com
Will Soligenix Inc. (DOA) stock keep high P E multiples2025 Pullback Review & Risk Controlled Daily Plans - newser.com
Is Soligenix Inc. stock a buy for dividend growth2025 Market Overview & Trade Opportunity Analysis Reports - newser.com
Is Soligenix Inc. (DOA) stock a buy for dividend portfoliosJuly 2025 Weekly Recap & Fast Entry High Yield Stock Tips - newser.com
Will Soligenix Inc. (DOA0) stock profit from fiscal stimulus2025 Price Action Summary & Consistent Profit Focused Trading Strategies - newser.com
Can Soligenix Inc. (DOA) stock deliver strong annual returns2025 Market Outlook & Daily Profit Maximizing Trade Tips - newser.com
Is Soligenix Inc. (DOA0) stock safe for risk averse investorsMarket Activity Summary & Safe Investment Capital Preservation Plans - newser.com
Soligenix hits enrollment target for CTCL treatment interim analysis By Investing.com - Investing.com Nigeria
Is Soligenix Inc. (DOA0) stock cheap vs fundamentalsJuly 2025 Intraday Action & AI Enhanced Execution Alerts - newser.com
Soligenix (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte - Digital Journal
Is Soligenix Inc. trending in predictive chart modelsJuly 2025 Spike Watch & Weekly Market Pulse Alerts - newser.com
Is Soligenix Inc. (DOA0) stock attractive for growth fundsDollar Strength & AI Enhanced Execution Alerts - newser.com
Will Soligenix Inc. (DOA) stock extend growth storyMarket Movement Recap & Free Technical Pattern Based Buy Signals - newser.com
Soligenix Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte for Cutaneous T-Cell Lymphoma – citybuzz - citybuzz
Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte - TipRanks
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - The Malaysian Reserve
Soligenix achieves enrollment milestone for planned interim analysis in confirmatory phase 3 clinical trial of HyBryte for treatment of cutaneous T-cell lymphoma - MarketScreener
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of Hybryte?? for the Treatment of Cutaneous T-Cell Lymphoma - MarketScreener
Soligenix hits enrollment target for CTCL treatment interim analysis - Investing.com
Soligenix (SNGX) Completes Key Enrollment for Phase 3 Study on C - GuruFocus
Soligenix Inc Stock (SNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):